Last updated: 02/18/2026 08:50:21
Comparison of Blenrep with bortezomib plus dexamethasone (BVd) versus Teclistamab plus daratumumab (Tec-Dara)
GSK study ID
308901
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Will be recruiting
Will be recruiting
Trial overview
Official title: Indirect Treatment Comparison of Belantamab Mafodotin plus Bortezomib and Dexamethasone versus Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
Trial description: The key question the current study aims to address is: What is the relative efficacy (in terms of Overall survival [OS]) and safety (in terms of treatment-emergent infections) of BVd versus Tec-Dara in adult participants with relapsed/refractory multiple myeloma (RRMM) who have received one to three prior lines of therapy, including a proteasome inhibitor (PI) and lenalidomide. Unanchored indirect treatment comparisons will be employed that collectively combine data across clinical trials of BVd (DREAMM-7) and Tec-Dara (MajeTEC-3) to produce estimates of BVd’s efficacy and safety relative to Tec-Dara.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Overall survival
Timeframe: Up to 36 months
Secondary outcomes:
Number of participants with Treatment-emergent infections of any grade
Timeframe: Baseline (Day 1) to 45 months
Number of participants with Treatment-emergent infections of grade 3 or 4
Timeframe: Baseline (Day 1) to 45 months
Interventions:
Not applicable
Enrollment:
0
Primary completion date:
2026-13-03
Observational study model:
Other
Time perspective:
Retrospective
Clinical publications:
Not applicable
Medical condition
Multiple Myeloma
Product
Not applicable
Collaborators
Not applicable
Study date(s)
February 2026 to March 2026
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- Clinical trials that included adult participants with RRMM who have received at least one prior line of therapy, including a PI and lenalidomide, and were then treated with BVd or Tec-Dara.
- Clinical trials that did not include adult participants with RRMM who have received at least one prior line of therapy, including a PI and lenalidomide, and trials that did not study BVd or Tec-Dara.
Inclusion and exclusion criteria
Inclusion criteria:
- Clinical trials that included adult participants with RRMM who have received at least one prior line of therapy, including a PI and lenalidomide, and were then treated with BVd or Tec-Dara.
Exclusion criteria:
- Clinical trials that did not include adult participants with RRMM who have received at least one prior line of therapy, including a PI and lenalidomide, and trials that did not study BVd or Tec-Dara.
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
No study documents available.
Results overview
No study documents available
Recruitment status
Will be recruiting
Actual primary completion date
Not applicable
Actual study completion date
Not applicable
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website